Phase II Study of Lenalidomide Maintenance in Patients With High Risk Acute Myeloid Leukemia (AML) in Remission

Trial Profile

Phase II Study of Lenalidomide Maintenance in Patients With High Risk Acute Myeloid Leukemia (AML) in Remission

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results (n=14) presented at the 22nd Congress of the European Haematology Association.
    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2016 Planned number of patients changed from 80 to 50.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top